口服VP_(16)联合DDP方案治疗非小细胞肺癌

Oral VP 16 Plus DDP Regimen for Non small Cell Lung Cancer

作者自１９９３年１月采用口服ＶＰ１６联合ＤＤＰ方案治疗非小细胞肺癌（ＮＳＣＬＣ）３５例，所有病例均由组织学检查证实。结果ＣＲ１例、ＰＲ１６例、Ｓ８例、Ｐ１０例，有效率（ＣＲ＋ＰＲ）４８．６％。全组中位生存期９．８个月。恶心、呕吐发生率为７８．３％，粘膜炎为１０．４％，白细胞和血小板降低发生率分别为５８．１％和１５．２％，大多为轻、中度。作者认为ＶＰ１６对小细胞肺癌（ＳＣＬＣ）的疗效有显著的时间依赖性，长时间、低剂量口服ＶＰ１６对ＳＣＬＣ有较好的疗效，但对ＮＳＣＬＣ的疗效是否更好，本文尚未证明。然而，方便给药，利于门诊化疗是其优点。

Cases of non small cell lung cancer (NSCLC) proved histologically were treated with oral VP 16 capsule plus DDP since January 1993. The results showed that 1 cases achieved CR,16 cases PR, 8 cases S and 10 cases P. The reponse rate (CR+PR) was 48.6%, The median survival term of the whole group was 9.8 months. The incidences of nausea and vomiting were 78.3%, mucositis was 10.4%, and the incidences of leucopenia, thrombocytopenia were 58.1% and 15.2%,respectively. Most cases were mild to moderate. In conclusion, It seem that VP 16 demonstrates remarkable schedule dependency in small cell lung cancer(SCLC). Chronic and low dose oral VP 16 regimen can produce more superior efficacy in SCLC,but it has not been proved in NSCLC in this paper. Nevertheless,convenient to dose and benefit to outpatient chemotherapy are advantages of this regimen.